Introduction {#s1}
============

Febrile neutropenia (FNP) is a common and potentially life-threatening complication of therapy for childhood cancer, which has increasingly been subject to targeted treatment based on clinical risk stratification [@pone.0038300-Phillips1]. For children this move towards risk-directed care is based upon evidence of the low incidence of death [@pone.0038300-Dommett1], the majority of patients being without identified significant infection or sepsis [@pone.0038300-Phillips2], and small randomised trials demonstrating the feasibility of out-patient based treatment for patients at low-risk of septic complications [@pone.0038300-Teuffel1]. A large proportion of the evidence for risk stratifications has originated from adult oncology [@pone.0038300-Freifeld1] It is acknowledged that children are not 'little adults' but distinct in the biology of their malignancies, treatment regimens, infections and psychosocial setting and therefore specific evidence for stratification of children with FNP is needed [@pone.0038300-Sung1].

Since we undertook a systematic review and meta-analysis of risk stratification systems in 2008 [@pone.0038300-Phillips2], further studies have been published which address this issue [@pone.0038300-Ammann1]. Accordingly we have updated our review to summarise the most recent advances in our knowledge of evidence on the discriminatory ability and predictive accuracy of such risk stratification clinical decision rules (CDR) for children and young people with cancer.

Methods {#s2}
=======

This update review was conducted in accordance with "Systematic reviews: CRD\'s guidance for undertaking reviews in health care" [@pone.0038300-Centre1] and registered on the PROSPERO Registry of systematic reviews: CRD42011001685. It sought studies which aimed to derive or validate a CDR in children or young people (aged 0--18 y) presenting with febrile neutropenia. Both prospective and retrospective cohorts were included, but those using a case-control ("two-gate") approach were excluded as these have been previously shown to exaggerate diagnostic accuracy estimates [@pone.0038300-Lijmer1].

Search strategy and selection criteria {#s2a}
--------------------------------------

The electronic search strategy [@pone.0038300-Phillips2] was reviewed and repeated on the following databases from February 2009 to September 2011:

-   MEDLINE

-   MEDLINE In-Process & Other Non-Indexed Citations

-   EMBASE

-   CINAHL

-   Literatura Latinoamericana y del Caribe en Ciencias de la Salud (LILACS)

Reference lists of relevant systematic reviews and included articles were reviewed for further relevant articles. Published and unpublished studies were sought and no language restrictions applied. Non-English language studies were translated. Two reviewers independently screened the title and abstract of studies for inclusion, and then the full text of retrieved articles. Disagreements were resolved by consensus.

Validity assessment and data extraction {#s2b}
---------------------------------------

The validity of each study was assessed as with our previous review using 11 of the 14 questions from the QUADAS assessment tool for diagnostic accuracy studies [@pone.0038300-Whiting1].

Data were extracted by one reviewer and checked by the other. The data extracted included age and sex distribution of the included participants, geographical location of the study, the participant inclusion/exclusion criteria, and the performance of the CDR as a 2\**k* table (where *k* refers to the number of strata described) or as sensitivity/specificity, as well as aspects of the methods used to derive the CDR (where applicable).

Methods of analysis/synthesis {#s2c}
-----------------------------

Where possible, data from new publications were added to meta-analyses undertaken in the original review [@pone.0038300-Phillips2]. Quantitative synthesis was undertaken when more than 2 studies tested the same CDR, and where appropriate, was investigated for sources for heterogeneity. For this update review, only dichotomous test data were found. For CDR with 3 datasets, a univariate approach was used (pooling sensitivity and specificity separately) [@pone.0038300-Simel1]. For those with 4 or more, a bivariate model was fitted using 'metandi' in STATA10 [@pone.0038300-Harbord1]. The protocol specified a random-effects meta-analysis was undertaken using WinBUGS 1.4.3 [@pone.0038300-Lunn1] for tests with 3 or more risk strata, but no data were found eligible for this analysis.

Heterogeneity between study results was explored through consideration of study populations, study design, CDR and outcomes chosen, although the small number of studies in each category limited this approach. Sensitivity analysis was undertaken by comparing results when the original (derivation) data set was included and excluded.

For those areas where a quantitative synthesis was not possible, a narrative approach was used.

Results {#s3}
=======

9 articles reporting on 8 studies were eligible for inclusion in the review (see [Figure 1](#pone-0038300-g001){ref-type="fig"}). The studies included patients from 2 month to 22 years old, with a wide range of malignancies, and a total of 2591 episodes of FNP describing four groups of outcomes: death, critical care requirement, serious medical complication, and bacteraemia. Six studies undertook prospective data collection, two retrospective. Details of the CDR included in this review are given in [Table 1](#pone-0038300-t001){ref-type="table"}.

![Flowchart of studies through the review.](pone.0038300.g001){#pone-0038300-g001}

10.1371/journal.pone.0038300.t001

###### Clinical decision rules examined.

![](pone.0038300.t001){#pone-0038300-t001-1}

                                                                                        Patient and disease related factors                                                                                                                  Episode specific factors                                                                                                                                       Rule formulation                                                                   Outcome                                                                                          Inclusion criteria                                                                                                                                                                                     Exclusion criteria
  ------------------------------------------------------ ------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- ----------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Klaassen [@pone.0038300-Klaassen1]                                                                   None                                                                                                                                   Absolute monocyte count                                                                                                                 Absolutely monocyte count \>100/mm3 = low risk of bacteraemia                                Significant bacterial infection                  ANC \<500cells/mm^3^ or ≤1000cells/mm^3^ and falling. Temperature \>38.0°C ≥2 occasions in ≥12 h, or once \>38.5°C, or localised infection                 New malignant diagnosis; bone marrow or stem-cell transplantation in preceding 6 months. Another medical condition that independently required inpatient observation. Interstitial infiltrate or lobar consolidation on chest x-ray
  Alexander [@pone.0038300-Alexander1]                     AML, Burkitts lymphoma, induction ALL, progressive disease, relapsed with marrow involvement     Hypotension, tachypnea/hypoxia \<94%, new CXR changes, altered mental status, severe mucositis, vomiting or abdominal pain, focal infection, other clinical reason for in-patient treatment                           Absence of any risk factor = low risk of serious medical complication                              Significant adverse outcome                                                             ANC ≤500/mm^3^, temperature \>38.5°C. Outpatient status.                                                                                                                                                               Post stem cell transplant
  Rondinelli [@pone.0038300-Rondinelli1]                                  2 points for central venous catheter, 1 point for age \>5 years                                                      4.5 points for clinical site of infection,2.5 points for no URTI, 1 point each for fever \>38.5°C, hemoglobin ≤7 g/dL                                                                  Total score \<6 = low risk of serious infectious complication                               Serious infectious compllications   ANC \<500cells/mm^3^ or ≤1000cells/mm^3^ and falling, temperature ≥37.8°C ≥3 occasions in ≥24 h, or once \>38.0°C. First episode per patient (new or relapsed disease)                                                    Second or subsequent episode. Episodes in progressive disease (\<6 m from between completing therapy and relapse). History of BMT
  PINDA [@pone.0038300-Santolaya2]                                           Relapsed leukaemia, chemotherapy within 7 days of episode                                                                                             CRP ≥90 mg/dL, hypotension, platelets ≤50 G/L                                                                          Zero risk factors or only low platelets or only \<7 days from chemotherapy = low risk of invasive bacterial infection     Invasive bacterial infection                                            ANC ≤500cells/mm^3^, axillary temperature ≥38.0°C ≥2 occasions 1 h apart, or once ≥38.5°C                                                                                                                                                     Not reported
  Ammann [@pone.0038300-Ammann2]                                       Bone marrow involvement, central venous catheter, pre-B-cell leukemia                                                   Absence of clinical signs of viral infection, CRP \>50 mg/dL, white blood cell count \<0.5 G/L, hemoglobin \>10 g/dL                                                                  Three or fewer risk factors = low risk of significant infection                                    Significant infection                           Age 1--18 y, episode following non-myleoablative chemotherapy, temperature \>38.5°C or \>38°C for \>2 h, and ANC \<500 cells/mm^3^                                                                                                                           High dose chemotherapy
  SPOG (Adverse events rule) [@pone.0038300-Ammann1]           Applied after 24 hours: 4 points for chemotherapy more intensive than ALL maintenance                        Applied after 24 hours: 5 points for hemoglobin \>90 g/L, 3 points each for white blood cell count \<0.3 G/L, platelet \<50 G/L, any adverse event occurred                                                     Total score \<9 = low risk of adverse FN outcome                                         Significant adverse outcome                        Age 1--18 y, episode following non-myleoablative chemotherapy, temperature \>38.5°C or \>38°C for \>2 h, and ANC \<500 cells/mm^3^                                                                                                                           High dose chemotherapy
  SPOG (Bacteraemia rule) [@pone.0038300-Agyeman1]                                                     None                                                                               Applied after 24 hours: shaking chills ever observed, haemoglobin \>90 g/L, platelet \<50 G/L, any other need for IP treatment                                                           No risk factors = low risk of bacteraemia presenting after 24 hours                                Late bacteraemia (\>24 h)                         Age 1--18 y, episode following non-myleoablative chemotherapy, temperature \>38.5°C or \>38°C for \>2 h, and ANC \<500 cells/mm^3^                                                                                                                           High dose chemotherapy
  Hakim [@pone.0038300-Hakim1]                                          Score from cancer diagnosis: AML = 20, ALL/lymphoma = 7, Solids = 0                                                     Clinical presentation of serious unwell or toxic = 14, fever at presentation: ≥39°C = 11, ANC \<100/mm3 = 10 points                                                                    Total score \<24 = low risk of serious infection or sepsis                                    Serious infection or sepsis                                                 Outpatient, temperature \>38.3°C or \>38°C for \>1 h, and ANC \<500 cells/mm^3^                                                                                                                                           Inpatients, stem cell transplant recipients
  Hakim [@pone.0038300-Hakim1]                            Score from cancer diagnosis: AML = 11, others = 0. Relapsed disease = 11. Non-white patient = 8                                                                      Clinical presentation of serious unwell or toxic = 20                                                                                                     Total score \<20 = low risk of any medical complication                                      Any medical complication                                                   Outpatient, temperature \>38.3°C or \>38°C for \>1 h, and ANC \<500 cells/mm^3^                                                                                                                                           Inpatients, stem cell transplant recipients
  Delebarre [@pone.0038300-Delebarre1] (abstract only)       1 point for hematological malignancy, chemotherapy at high-risk of prolonged neutropenia,              1 point for clinical signs of local infection, fever \>39°C, white cell count \<500/mm3 or monocytes \<100/mm3 and procalcitonin \>0.3 ng/ml. TWO points for severe sepsis.                                                           High risk \>1 point.                                                            Severe infection                                                                                           Unclear                                                                                                                                                                                                 Unclear
  Mian [@pone.0038300-Mian1] (abstract only)                                                                                                                                                                             No clear rule -- uses postive blood culture result and raised CRP                                                                                                                    No clear rule                                                           Intensive care admission                                                                                       Unclear                                                                                                                                                                                                 Unclear
  Badiei [@pone.0038300-Badiei1]                                                                                                                                                                          Platelets \<20 g/dL, temperature ≥39°C, ANC \<100/mm3, mucositis, abnormal CXR on presentation                                                                      Risk of infection greater with more risk factors: no single threshold applied                          Life threatening infection                                                   Outpatient, temperature \>38.5°C or \>38°C for \>1 h, and ANC \<500 cells/mm3                                                                                                                                          BMT, Fever with new diagnosis, inpatient status

AML = acute myeloid leukaemia; ANC = Absolute neutrophil count; BMT = bone marrow transplant; CXR = chest radiograph; CRP = C-reactive protein; PINDA = Programa Infantil Nacional de Drogas Antineoplásticas; SPOG = Swiss Pediatric Oncology Group; URTI = upper respiratory tract infection.

Quality assessment {#s3a}
------------------

The studies varied in quality. Potential biases due to threats to independent outcome assessment were present in two studies [@pone.0038300-Dommett1], [@pone.0038300-Delebarre1], verification bias in two [@pone.0038300-Dommett1], [@pone.0038300-Ammann1], and two were presented only as abstracts [@pone.0038300-Delebarre1], [@pone.0038300-Mian1]. Five definitions of febrile neutropenia were used, with five definitions of fever and two of neutropenia. However, all definitions were clinically similar, with variation was mainly in the duration of time for a lower temperature to be considered 'prolonged'.

New CDR derivations {#s3b}
-------------------

Five studies attempted to derive at least one CDR. Four studies examined rules to predict significant medical complications; a group of outcomes generally encompassing death, intensive care admission, significant bacterial or fungal infection, and need for organ support such as supplemental oxygen, inotropes or dialysis [@pone.0038300-Ammann1], [@pone.0038300-Delebarre1], [@pone.0038300-Hakim1], [@pone.0038300-Badiei1]. Two examined rules to predict bacteraemia [@pone.0038300-Hakim1], [@pone.0038300-Agyeman1], and one intensive care admission [@pone.0038300-Mian1]. In one case a clear CDR could not be assessed [@pone.0038300-Mian1]. The CDR used data from the initial/admission assessment, or from a later assessment after approximately 24 hours of observation. The new CDR generally had high sensitivity for the chosen outcome at the expense of poor specificity (see [Table 2](#pone-0038300-t002){ref-type="table"}) and considered patient-disease, patient-episode and laboratory factors. Considerable imprecision in the estimates was seen, due mainly to the small numbers in individual studies (fewer than 350 patients).

10.1371/journal.pone.0038300.t002

###### Diagnostic test accuracy of newly described CDR.

![](pone.0038300.t002){#pone-0038300-t002-2}

                                                                     Number of patients   Number of episodes                 Age of patients                              Outcome               Number with poor outcome   Proportion in low risk group                Sensitivity                               Specificity
  ----------------------------------------------------------------- -------------------- -------------------- ---------------------------------------------- --------------------------------- -------------------------- ------------------------------ ---------------------------------------- -----------------------------------------
  Hakim [@pone.0038300-Hakim1]                                              332                  332           Median 6 yrs, range 2.4 months to 21.6 years     Serious infection or sepsis                47                          69%                    74.5% (95% CI 60.5% to 84.7%)             76.4% (95% CI 71.1% to 81.1%)
                                                                                                                                                                   Medical complications                   40                         63.7%                   77.5% (95% CI 62.5% to 87.7%)             69.5% (95% CI 63.9% to 74.5%)
  Delebarre [@pone.0038300-Delebarre1](abstract only)                       146                  316           Mean age 8 years, range 0.5 yrs to 17.5 yrs                                                 70                         20.6%                   98.6% (95% CI 92.3% to 99.7%)              26% (95% CI 20.9% to 31.8%)
  Badiei [@pone.0038300-Badiei1], Threshold value: 0 risk factors            68                  120                          Mean 5.9 years                    Life threatening infection                 35                         29.2%                   97.1% (95% CI 85.5% to 99.5%)              40% (95% CI 30.2% to 50.6%)
  1 risk factor                                                                                                                                                                                            35                         64.2%                   71.4% (95% CI 54.9% to 83.7%)              78.8% (95% CI 69% to 86.2%)
  2 risk factors                                                                                                                                                                                           35                          75%                    62.9% (95% CI 46.3% to 76.8%)             90.6% (95% CI 82.5% to 95.2%)
  3 risk factors                                                                                                                                                                                           35                          85%                     40% (95% CI 25.6% to 56.4%)              95.3% (95% CI 88.5% to 98.2%)
  4 risk factors                                                                                                                                                                                           35                         98.3%                    5.7% (95% CI 1.6% to 18.6%)               100% (95% CI 95.7% to 100%)
  SPOG [@pone.0038300-Ammann1] (Adverse events rule)                        206                  423             6.9 years (IQR 3.8 years to 11.6 years)      Serious adverse medical outcome             122                          35%                92% (IQR 91% to 93%, range 90% to 98%)   45% (IQR, 38% to 49%, range 12% to 57%)
  SPOG [@pone.0038300-Agyeman1] (Bacteraemia rule)                                                                                                                   Late bacteraemia                      67                          36%                         93% (IQR 91% to 97%)                     41% (IQR 21% to 45%)

CI = confidence intervals; IQR = interquartile range.

The newly derived CDR were subject to validation by internal statistical means (cross-validation) or in one alternative data set (see [Table 3](#pone-0038300-t003){ref-type="table"}). In all except one case [@pone.0038300-Mian1], multivariable regression analysis was used to build the model. One rule was built with a classification and regression tree (CART) approach [@pone.0038300-Mian1].

10.1371/journal.pone.0038300.t003

###### Validations of rules.

![](pone.0038300.t003){#pone-0038300-t003-3}

  Rule                                                                                      Number of patients   Number of episodes                            Age of patients                                           Outcome                   Proportion in low risk group                Sensitivity                               Specificity
  ---------------------------------------------------------------------------------------- -------------------- -------------------- ------------------------------------------------------------------- ---------------------------------------- ------------------------------ ---------------------------------------- -----------------------------------------
  **[Klaassen rule]{.ul}**                                                                                                                                                                                                                                                                                                
  **Klaassen** [@pone.0038300-Klaassen1] (derivation)                                              140                  227                   Median 6.8 y (range 6 m to 17 y: derivation set)               Significant bacterial infection                   37%                    87.5% (95% CI 76.4% to 93.8%)             41.2% (95% CI 35.9% to 46.6%)
  Amman [@pone.0038300-Ammann1]                                                                    206                  423                        6.9 years (IQR 3.8 years to 11.6 years)                   Serious adverse medical outcome                   38%                    86.9% (95% CI 79.8% to 91.8%)             48.5% (95% CI 42.9% to 54.1%)
  Macher [@pone.0038300-Macher1]                                                                   167                  377                             Median 6 y, range7 m to 19 y                         Significant bacterial infection                   40%                    79.3% (95% CI 61.6% to 90.2%)              45% (95% CI 35.9% to 54.3%)
  Baorto [@pone.0038300-Baorto1]                                                                   558                  1171                           Mean 8.0 y (range 1 y to 23 y)                                  Bacteraemia                             21%                    88.9% (95% CI 83.6% to 92.6%)             22.4% (95% CI 19.9% to 25.1%)
  Madsen [@pone.0038300-Madsen1]                                                                    76                  157                             Mean 8 y (range 2 m to 18 y)                      Microbiologically documented infection               39%                    91.7% (95% CI 74.2% to 97.7%)              41% (95% CI 35.5% to 46.8%)
  Rackoff [@pone.0038300-Rackoff1]                                                                  72                  172                           Range 9 m to 18 y: derivation set                                Bacteraemia                             19%                     100% (95% CI 89.8% to 100%)              23.2% (95% CI 16.9% to 30.9%)
  **[Ammann 2003 rule]{.ul}**                                                                                                                                                                                                                                                                                             
  **Ammann** [@pone.0038300-Ammann2] (derivation)                                                  132                  364                                     Not reported                                    Severe bacterial infection                     14%                     100% (95% CI 95.9% to 100%)               22.7% (95% CI 16.8% to 30%)
  SPOG [@pone.0038300-Ammann1]                                                                     206                  423                        6.9 years (IQR 3.8 years to 11.6 years)                      Severe bacterial infection                     10%                    96.7% (95% CI 91.9% to 98.7%)             12.3% (95% CI 9.1% to 16.5%)
  Macher [@pone.0038300-Macher1]                                                                   167                  377                             Median 6 y, range7 m to 19 y                            Severe bacterial infection                      8%                    95.2% (95% CI 86.9% to 98.4%)              9.1% (95% CI 6.4% to 12.8%)
  **[Alexander rule]{.ul}**                                                                                                                                                                                                                                                                                               
  **Alexander** [@pone.0038300-Alexander1] (derivation)                                            104                  188                                  Mean 8.9 y, SD 5.7                                Adverse medical complication                    58%                    84.6% (95% CI 57.8% to 95.7%)             64.6% (95% CI 53.8% to 74.1%)
  SPOG [@pone.0038300-Ammann1]                                                                     206                  423                        6.9 years (IQR 3.8 years to 11.6 years)                     Adverse medical complication                     8%                    94.3% (95% CI 88.6% to 97.2%)               8.6% (95% CI 6% to 12.4%)
  Dommett [@pone.0038300-Dommett1]                                                                 368                  762           Median age 5 years 7 months (range 1 month to 17 years 6 months).        Adverse medical complication                    53%                     58.7% (95% CI 52.2% to 65%)               57.9% (95% CI 53.7% to 62%)
  **[Programa Infantil Nacional de Drogas Antineoplásticas (PINDA) Rule]{.ul}**                                                                                                                                                                                                                                           
  **Santolaya** (derivation) [@pone.0038300-Santolaya2]                                            257                  447                             Mean 7 y (range 6 m to 18 y)                           Invasive bacterial infection                    43%                    85.4% (95% CI 79.5% to 89.8%)             64.6% (95% CI 58.2% to 70.5%)
  Santolaya (validation) [@pone.0038300-Santolaya1]                                                170                  263                             Mean 7 y (range 7 m to 17 y)                           Invasive bacterial infection                    40%                    92.1% (95% CI 86.5% to 95.6%)             76.4% (95% CI 68.2% to 83.1%)
  SPOG [@pone.0038300-Ammann1]                                                                     206                  423                        6.9 years (IQR 3.8 years to 11.6 years)                     Invasive bacterial infection                    15%                    93.4% (95% CI 87.6% to 96.6%)             18.9% (95% CI 14.9% to 23.7%)
  Macher [@pone.0038300-Macher1]                                                                   167                  377                             Median 6 y, range7 m to 19 y                           Invasive bacterial infection                    46%                     66.7% (95% CI 51% to 79.4%)              48.1% (95% CI 41.4% to 54.8%)
  **[Swiss Pediatric Oncology Group (SPOG) 2010 Rule]{.ul}**                                                                                                                                                                                                                                                              
  **SPOG** [@pone.0038300-Ammann1] (Adverse events rule derivation)                                206                  423                        6.9 years (IQR 3.8 years to 11.6 years)                   Serious adverse medical outcome                   35%                92% (IQR 91% to 93%, range 90% to 98%)   45% (IQR, 38% to 49%, range 12% to 57%)
  Miedeima [@pone.0038300-Miedema1]                                                                110                  210                    Median 6.6 years (IQR 4.3 years to 10.8 years)                Serious adverse medical outcome                   50%                       82% (95% CI, 77% to 87%                  57% (95% CI, 50% to 64%)
  **[Rondinelli Rule]{.ul}** [@pone.0038300-Rondinelli1] **[(no derivation data)]{.ul}**                                                                                                                                                                                                                                  
  Macher [@pone.0038300-Macher1]                                                                   167                  377                             Median 6 y, range7 m to 19 y                            Severe bacterial infection                     N/A                             62% (36--82)                             43% (34--52)
  SPOG [@pone.0038300-Ammann1]                                                                     206                  423                        6.9 years (IQR 3.8 years to 11.6 years)                      Severe bacterial infection                     35%                     84.4% (95% CI 77% to 89.8%)              43.2% (95% CI 37.7% to 48.8%)

Validation of CDR {#s3c}
-----------------

Four studies [@pone.0038300-Dommett1], [@pone.0038300-Ammann1], [@pone.0038300-Miedema1], [@pone.0038300-Macher1] were explicit in undertaking validations of 9 previously described CDR. These universally demonstrated poorer discriminatory ability when tested in alternative data sets (see [Table 3](#pone-0038300-t003){ref-type="table"}). The geographical settings for validations of the rules varied from those where the rule had been derived.

Synthesis of CDR accuracy {#s3d}
-------------------------

Meta-analysis was undertaken for two CDR; the "Klaassen" rule and the "Ammann" rule. Two further CDR, the PINDA rule and the "Alexander" rule, have not been subject to meta-analysis as the results are too heterogeneous, these results are presented graphically. Two further CDR, the Rondellini rule and the SPOG2003 rule, have been assessed in two datasets, too few to perform meaningful meta-analysis. No data were available to update the three-stratum "Rackoff" rule meta-analysis of the previous study [@pone.0038300-Phillips2].

The "Klaassen" rule is based on a single feature: an absolute monocyte count of greater than 100/mm^3^ to predict patients less likely to have significant infection. Data were pooled from 4 studies from the previous review [@pone.0038300-Rackoff1], [@pone.0038300-Baorto1], [@pone.0038300-Madsen1], [@pone.0038300-Klaassen1] and two new sources [@pone.0038300-Ammann1], [@pone.0038300-Macher1]. The results of this analysis give a pooled average sensitivity of 88% (95% CI 84 to 91%) and specificity of 36% (95% CI 27 to 45%), see [Figure 2](#pone-0038300-g002){ref-type="fig"}.

![Individual and pooled diagnostic test accuracy of 'Klaassen' rule.\
The ROC space plots show each study estimates of sensitivity and specificity as a marker at the point estimate, with 95% confidence intervals demonstrated by lines. In reading such graphs, tests with a better discriminatory ability fall in the top left corner of the plot, and non-discriminatory tests fall on a 45° line between the bottom left and top right. The light lines and circles represent individual studies, with the darker dashed lines showing the study from which the rule was derived. The dark circle is the pooled estimate of sensitivity and specificity, and the dashed ellipse represents the bivariate 95% confidence intervals of this result.](pone.0038300.g002){#pone-0038300-g002}

The "Ammann" rule describes patients at low risk of significant bacterial infection as from weighted factors including: bone marrow involvement, clinical signs of viral infection, serum C-reactive protein (CRP) level, leukocyte count, presence of a central venous catheter, high haemoglobin level, and diagnosis of pre-B-cell leukaemia (see [Table 1](#pone-0038300-t001){ref-type="table"} for details). Three studies provide data to test this rule [@pone.0038300-Ammann1], [@pone.0038300-Agyeman1], [@pone.0038300-Macher1]. The pooled average sensitivity was 98% (95%CI 91 to 99%) but pooled average specificity only 13% (95% CI 8% to 21%), see [Figure 3](#pone-0038300-g003){ref-type="fig"}.

![Individual and pooled diagnostic test accuracy of 'Ammann' rule.\
The ROC space plots here has the light lines and circles represent individual studies, with the darker dashed lines showing the study from which the rule was derived, and the heavy dark lines the pooled estimate of sensitivity and specificity, with the univariate 95% confidence intervals.](pone.0038300.g003){#pone-0038300-g003}

The "Alexander" rule examined adverse clinical consequences, using a combination of clinical features which predict prolonged neutropenia, and significant co-morbidities at presentation. This rule was assessed by two further studies [@pone.0038300-Dommett1], [@pone.0038300-Agyeman1]. There was marked heterogeneity in the results of these three studies (see [Figure 4](#pone-0038300-g004){ref-type="fig"}). When used at reassessment after 48 hrs of hospitalisation, there was marked improvement in the discriminatory ability of the rule [@pone.0038300-Dommett1] (sensitivity = 100%, specificity = 39%).

![Individual diagnostic test accuracy of 'Alexander' rule.\
The light lines and circles represent individual studies, with the darker dashed lines showing the study from which the rule was derived.](pone.0038300.g004){#pone-0038300-g004}

The PINDA rule again describes patients at low risk of significant bacterial infection as from weighted factors including laboratory and chemotherapy related parameters. This has been examined in two studies from the Santolya group [@pone.0038300-Santolaya1], [@pone.0038300-Santolaya2] and by two validations from European centres [@pone.0038300-Ammann1], [@pone.0038300-Macher1]. There was marked heterogeneity (see [Figure 5](#pone-0038300-g005){ref-type="fig"}), potentially explained through geographical variation: the rule worked well applied in the population in Chile, but failed to differentiate patients in French and Swiss/German studies.

![Individual and pooled diagnostic test accuracy of 'PINDA' rule.\
The light lines and circles represent individual studies, with the darker dashed lines showing the study from which the rule was derived.](pone.0038300.g005){#pone-0038300-g005}

The rule of Rondellini [@pone.0038300-Rondinelli1] is a weighted score of clinical and haematological parameters (see [Table 1](#pone-0038300-t001){ref-type="table"} for details) and was assessed in two validation datasets. These demonstrated a sensitivity of 84% [@pone.0038300-Ammann1] and 62% [@pone.0038300-Macher1] and both estimated specificity at 43%.

The SPOG2003 is a weighted score of haematological parameters with intensity of chemotherapy. It is applied after 8--24 hours of hospitalisation. This model was shown to have a sensitivity 92% and specificity of 45% [@pone.0038300-Ammann1]. A validation of this model demonstrated poorer sensitivity (82%) and slightly better specificity (57%) [@pone.0038300-Miedema1].

Discussion {#s4}
==========

This update systematic review builds on previous work to bring our knowledge of currently developed clinical decision rules for risk stratification in paediatric febrile neutropenia up to date. Now nine further models have been described, bringing the total to 25, and have included 10,000 episodes. It remains the case that no one rule is clearly better than any other, but we are now more clearly aware of the limitations of CDR which have not been subject to temporal and geographical validation.

The majority of CDR in this review focus upon defining a group at 'low risk' of complications. These rules once again have clinical and physiological similarities. The dominant themes are of a relationship between underlying diagnosis, chemotherapeutic regime, and clinical and laboratory parameters at the outset of the episode of fever. A further finding from this review is the demonstration that undertaking risk stratification at 24--48 hours after the onset of the episode leads to much greater discrimination, as many occult infections will have declared in this period.

Two rules have shown relative consistency of results. These are the simplest stratification of patients using the criteria of absolute monocyte count \>100/mm^3^ to define a low risk group [@pone.0038300-Klaassen1]. This has a pooled average sensitivity of 88% (95% CI 84 to 91%) and specificity of 36% (95% CI 27 to 45%), and if we assume serious infectious events occur in 30% of the group, the low-risk group has a 9% risk of serious infection, and accounts for approximately 29% of the total population. The high risk group has a 37% risk of infectious complications.

The Ammann 2003 rule [@pone.0038300-Ammann1] has much better sensitivity (estimated at 98%), leading to a risk of serious infectious complications in around 5% cases, but would only class 9% of patients as low risk, making it of little practical use.

Other further rules have shown marked heterogeneity: the Alexander rule [@pone.0038300-Alexander1] and the PINDA rule. The data support the use of the PINDA rule in Chile, where it has been successfully validated [@pone.0038300-Santolaya1], but do not support its use in Europe. A similar situation exists with the Brazilian rule [@pone.0038300-Rondinelli1] which again was not successfully validated in European data sets. The Alexander rule did not successfully differentiate patients at admission in the UK and Europe, but its use at a 48 hour reassessment was associated with successful reductions in hospital stay. A further, newer, rule from the SPROG group requires more validation before a decision can be made on its usefulness.

These findings, that validation of CDR may be poor in comparison to derivation, and that geographical variation may mean CDR fail to work universally, have important clinical implications. There is a wealth of examples in the statistical and methodological literature regarding the over-optimism of newly derived CDR [@pone.0038300-Janssen1], [@pone.0038300-Toll1]. The core concept is that rules derived from one dataset fit the idiosyncrasies and anomalies of the data collected, rather than reflecting the predictive power in the whole population of children experiencing FNP. However, these frequently equation-laden papers are uncommonly read by clinicians, and the complex approaches suggested to 'shrinking' the CDR values to increase their reproducibility are tricky to understand and to implement. The finding of geographical variation is potentially through different interpretations of similar findings; for example, how "unwell" should a child appear before they fall into this diagnostic category? There may also be subtle differences in the regimes used, as an example the use of steroid pulses in maintenance treatment for acute lymphoblastic leukaemia varies across Europe, and this may affect the CDR discriminatory ability.

This review has demonstrated there is an increasingly wide range of rules mainly for the prediction of an absence of adverse outcomes during episodes of febrile neutropenia in children, despite the existence of at least sixteen other applicable CDR [@pone.0038300-Phillips2]. Six rules have been subject to further verification, each demonstrating a variable degree of over-optimism in the original reports when the CDR is applied in different settings. The small size of these reports, with low ratios of events per variable examined may explain some of the variability in factors selected and poor reproducibility, as may undefined aspects of geographical differences between populations.

The practical application of these CDR requires it to be appropriate to the healthcare setting, and validated in the setting in which it is to be used. There remains a need for further research to reduce uncertainty around the efficiency of CDR, and potentially generate a very robust model on the basis of a much larger dataset, with well over 20 events per variable under examination. Importantly, rules should also identify a group at the highest risks of complications, to concentrate hopefully lifesaving early sepsis interventions in this group [@pone.0038300-Dellinger1]. This project is already underway, with the PICNICC collaboration having collected data on around 5000 episodes of febrile neutropenia from 18 collaborating groups across North & South America, Europe and Asia.
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